Patent ID: 11892454
Assignee: CELLACT PHARMA GMBH
Field: Measurement (Instruments)
Classification: CPC G  A  C | IPC A  C  G

Claim 1:
2. A method of assessing if a patient suffering from biliary tract cancer (BTC) is a responder to treatment with an ester prodrug of a chemotherapeutic agent and treating the patient if the patient is a responder, the method comprising the steps of
a) providing a BTC tumor sample of the patient,
b) determining the level of CES2 expression in the BTC tumor sample, wherein the expression of CES2 in the BTC tumor sample indicates that the patient is a responder to treatment with the ester prodrug of a chemotherapeutic agent, and wherein the lack of expression of CES2 in the BTC tumor sample indicates that the patient is a non-responder to treatment with the ester prodrug of a chemotherapeutic agent, and
c) (i) treating the patient with the ester prodrug of a chemotherapeutic agent if the patient is a responder, or
(ii) treating the patient with a treatment regimen that comprises a treatment that is different from the ester prodrug if the patient is a non-responder.